Clinical Trial Working Groups
|
|
Goal for 2014: One concept from each institution. To date, we've received concepts from 10 institutions! The 16 studies/concepts in the current BTCRC pipeline are outlined below.
Genitourinary
- Approved LOI: Renal cell carcinoma (Illinois)
- Concept: Prostate (Rutgers)
- Co-chairs: Mark Stein (Rutgers), Ajjai Alva (Michigan)
- Next call: TBD. See you at GU ASCO on Feb. 26!
Thoracic
- Concepts:
- Esophageal (Indiana)
- Esophageal (Iowa)
- Non-small cell lung cancer (Michigan)
- Small cell lung cancer (Nebraska)
- Non-small cell lung cancer with brain metastasis (Minnesota)
- Co-chairs: Arkadiusz Dudek (Illinois), Nasser Hanna (Indiana)
- Next call: TBD.
Gastrointestinal
Breast
- Concepts:
- First line triple negative metastatic breast cancer (Penn State)
- ER+ and/or PR+ and HER2- breast cancer (Illinois)
- Co-chairs: Deborah Toppmeyer (Rutgers), Kari Wisinski (Wisconsin)
- Next call: February 2015. See you in San Antonio on Dec. 11!
- Kick-off call held Nov. 11.
- Seeking two co-chairs. If interested, please send your CV and statement of interest to Andrea Hurd.
- Two concepts in early development, not yet presented to the working group.
- Next call: TBD.
Melanoma/Cutaneous Oncology
(now forming)
- Kick-off teleconference scheduled for Friday, Dec. 19 at 10 am ET / 9 am CT.
- Seeking representation from Iowa, Michigan, Michigan State, Minnesota, Purdue, and Wisconsin.
- Concept (to be presented during kick-off call): Squamous cell carcinoma of the skin (Rutgers)
Hematologic Malignancies
(now forming)
- AHQ has received interest in forming working groups in the areas of myeloid neoplasms, lymphoma, and myeloma.
- Face-to-face kick-off meeting at ASH on Dec. 8.
- Concept (not yet presented to working group): Chronic lymphocytic leukemia (Michigan)
|
|
 |
|
|
Visits to Member Institutions
|
 Susan Goodin, PharmD, executive officer of the Big Ten Cancer Research Consortium (BTCRC), recently began visits to member institutions to gain a better understanding of the scientific strengths at each institution and to identify collaborative research opportunities. During each visit, Dr. Goodin meets with the cancer center leadership, its Steering Committee representative, appropriate faculty and staff, and the Institutional Review Board to discuss BTCRC opportunities, procedures for trial development and conduct, budgeting, and philanthropy. The most recent visit was to the Masonic Cancer Center at the University of Minnesota, and visits to Iowa and Northwestern are currently being scheduled.
|
 Learn about Holden Comprehensive Cancer Center at the University of Iowa, our featured member for December, in this conversation with Director George Weiner, MD. Read more.
To see past member features, click here. |
- BTCRC IRB Initiative Breakfast during PRIM&R's 2014 AER Conference in Baltimore, MD, on Saturday, Dec. 6 at 7:00 a.m. ET, at the Baltimore Marriott Inner Harbor at Camden Yards, 110 S. Eutaw Street. We will meet in the Promenade Room. See map.
- Hematology Working Groups Kickoff Meeting at the American Society of Hematology (ASH) Annual Meeting on Monday, Dec. 8, noon to 1:30 p.m. PT, at the San Francisco Marriott Marquis, 780 Mission Street, San Francisco, CA. We will meet in the Sierra I Room.
See map.
- Breast Working Group meeting at the 2014 San Antonio Breast Cancer Symposium on Thursday, Dec. 11, 7:30 to 9:00 p.m. CT at the Hilton Palacio Del Rio, 200 S. Alamo Street, San Antonio, TX. We will meet in La Princesa Conference Room. See map.
|
The Big Ten Cancer Research Consortium introduced a new monthly feature in November highlighting news from our member institutions. We are proud of the work being done across the consortium, as we work together to improve the lives of all patients with cancer. Read more.
|
|
BTCRC Q&A: Regulatory and Safety
|
BTCRC administrative headquarters continues our Q&A series covering topics of interest to our member institutions. This month, we address a number of questions related to regulatory and safety, including:
- What are the responsibilities of BTCRC regulatory managers?
- What information should I send to the regulatory manager?
- What are common errors?
- If a trial requires an IND, who is the holder of the IND?
- To what regulatory authorities should I report my SAE and who does the reporting?
Read our full Q&A here.
|
|
|
